In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials ...

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid ...

A total of 57 abstracts will feature 13 approved and potential new medicines from across AstraZeneca’s portfolio and pipeline in haematology, including from Alexion, its rare disease group, with data ...

Detailed price information for Voyager Therapeut (VYGR-Q) from The Globe and Mail including charting and trades.

Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey ...

(In 2020, Alexion was bought by AstraZeneca for $39 billion.) “The thing that stood out from our time at Alexion was that ...

Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...

In a frothy market starved for value, these three dividend stocks combine reasonable valuations with the proven ability to ...

In two significant recent opinions, the Delaware Chancery Court ruled against the buyers of life sciences companies, holding that they failed to ...

The global geriatric care services market is set for remarkable expansion, with an anticipated Compound Annual Growth Rate ...

The 43 patients treated with ravulizumab had a 33.2% greater reduction in average urine protein to creatinine ratio (UPCR) ...